Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 4.1% – Time to Sell?

Stoke Therapeutics, Inc. (NASDAQ:STOK) traded down 4.1% during mid-day trading on Tuesday . The stock traded as low as $12.56 and last traded at $12.56. 42,943 shares traded hands during trading, a decline of 94% from the average session volume of 762,696 shares. The stock had previously closed at $13.10.

Analysts Set New Price Targets

A number of research analysts recently issued reports on STOK shares. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, September 11th. Leerink Partners began coverage on Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective for the company. Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Wedbush reissued an “outperform” rating and issued a $17.00 target price on shares of Stoke Therapeutics in a report on Thursday, July 11th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $20.83.

Stoke Therapeutics Stock Performance

The company has a fifty day moving average price of $13.26 and a two-hundred day moving average price of $13.70.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.11. The company had revenue of $4.83 million for the quarter, compared to analysts’ expectations of $3.33 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. On average, research analysts anticipate that Stoke Therapeutics, Inc. will post -2.1 EPS for the current year.

Insider Activity at Stoke Therapeutics

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the sale, the insider now directly owns 8,906,181 shares in the company, valued at $125,131,843.05. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 11.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

A number of large investors have recently bought and sold shares of STOK. Quest Partners LLC acquired a new position in shares of Stoke Therapeutics during the second quarter valued at about $29,000. Nisa Investment Advisors LLC increased its position in Stoke Therapeutics by 53.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after buying an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Stoke Therapeutics during the 2nd quarter worth approximately $123,000. State Board of Administration of Florida Retirement System acquired a new position in Stoke Therapeutics during the 1st quarter worth approximately $141,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after acquiring an additional 1,994 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.